Treating the cells with the cytokine cocktail while they are out of the body not only reduces their expression of CD38, a marker of exhaustion, but it also helps to ensure their function and ...

While the initial HexaBody-CD38 clinical data is promising and showed ... next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

It is thought that CD38-expressing cells contribute to disease ... in the kidneys and cause inflammation and loss of kidney function. Felzartamab's mode of action is to deplete those antibody ...

(RTTNews) - Genmab A/S (GMAB) Monday announced that Johnson & Johnson (JNJ) has decided not to exercise its option to develop and commercialize HexaBody-CD38 for multiple myeloma, for a worldwide ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38.

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical ... next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...